Yokoi, K., Ito, T., Maeda, Y., Nakajima, Y., Ueta, A., Nomura, T., Koyama, N., Kato, I., Suzuki, S., Kurono, Y., Sugiyama, N., and Togari, H
Sections were incubated with antibodies against PCNA (PC10) (cell signaling, 12 000) and IGF-1R (N-20) (Santa Cruz, 150)
doi: 10.1038/s41575020-00360-x 13 SiesH
Individual response varies your provider will guide frequency and duration based on your goals
The most rigorous publications include reconstitution volumes, final concentrations, syringe types, and injection timing as primary methods details rather than supplementary information, treating dose delivery as a reproducibility-critical variable equivalent to subject selection criteria or endpoint measurement protocols
It is not approved for therapeutic use and is intended strictly for laboratory and investigative research purposes